183 related articles for article (PubMed ID: 7851005)
1. Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro.
Parlevliet KJ; Chamuleau ME; Yong SL; Raasveld MH; ten Berge IJ; Schellekens PT
Clin Exp Immunol; 1995 Feb; 99(2):155-9. PubMed ID: 7851005
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet KJ; ten Berge IJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
J Clin Invest; 1994 Jun; 93(6):2519-25. PubMed ID: 8200988
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro.
Meijer RT; Yong SL; Surachno S; ten Berge IJ; Schellekens PT
Transplant Proc; 2001; 33(1-2):1229-30. PubMed ID: 11267271
[No Abstract] [Full Text] [Related]
4. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
[TBL] [Abstract][Full Text] [Related]
5. Non FcR-binding murine antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation.
Meijer RT; Yong SL; ten Berge IJ; van Lier RA; Schellekens PT
Clin Exp Immunol; 2001 Mar; 123(3):511-9. PubMed ID: 11298141
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.
Meijer RT; Surachno S; Yong SL; Bemelman FJ; Florquin S; Ten Berge IJ; Schellekens PT
Clin Exp Immunol; 2003 Sep; 133(3):485-92. PubMed ID: 12930378
[TBL] [Abstract][Full Text] [Related]
7. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.
Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J
Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519
[TBL] [Abstract][Full Text] [Related]
8. T cells from patients successfully treated with OKT3 do not react with the T-cell receptor antibody.
Gebel HM; Lebeck LK; Jensik SC; Webster K; Bray RA
Hum Immunol; 1989 Oct; 26(2):123-9. PubMed ID: 2479623
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
10. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.
Caillat-Zucman S; Blumenfeld N; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplantation; 1990 Jan; 49(1):156-60. PubMed ID: 2137271
[TBL] [Abstract][Full Text] [Related]
11. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
[TBL] [Abstract][Full Text] [Related]
12. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
13. Post-OKT3 induction therapy CD complex response predicts renal allograft rejection.
Stephan RN; Munschauer CE; Kohli RK; Sridhar NR; Hoover EL; Davidson IJ
Transplantation; 1997 Apr; 63(8):1183-6. PubMed ID: 9133483
[TBL] [Abstract][Full Text] [Related]
14. Study of induction of activation of human peripheral blood mononuclear cells with a non-activating form of anti-CD3 MoAb in autoimmune thyroid disease (AITD).
Resetkova E; Arreaza G; Yoshikawa N; Morita T; Kim H; Carayon P; Volpé R
Clin Exp Immunol; 1993 Mar; 91(3):397-403. PubMed ID: 8443962
[TBL] [Abstract][Full Text] [Related]
15. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex.
Ceuppens JL; Bloemmen FJ; Van Wauwe JP
J Immunol; 1985 Dec; 135(6):3882-6. PubMed ID: 2933454
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
17. Cross-species reactivity of the anti-idiotype anti-OKT3 cascade between mice and humans.
Carreno M; Fuller L; Zucker K; Yang WC; Burke G; Nery J; Gomez C; Esquenazi V; Miller J
Hum Immunol; 1992 Apr; 33(4):249-58. PubMed ID: 1386353
[TBL] [Abstract][Full Text] [Related]
18. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
19. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
